{"id":43642,"date":"2020-10-05T08:14:37","date_gmt":"2020-10-05T12:14:37","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=43642"},"modified":"2020-10-05T02:17:41","modified_gmt":"2020-10-05T06:17:41","slug":"merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642","title":{"rendered":"Merck &#038; Co\u2019s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron"},"content":{"rendered":"<p>Over the years, <strong>Merck &amp; Co\u2019s (NYSE:MRK)<\/strong> blockbuster cancer treatment, Keytruda, has been the standard first-line treatment alternative for most burdensome lung cancers, but this dominance is about to change. Recently at a cancer research conference, several companies challenged the treatment with their won cancer drugs.<\/p>\n<p><strong>Merck\u2019s blockbuster cancer treatment could face competition from new entrants <\/strong><\/p>\n<p>The most notable is <strong>Regeneron Pharmaceuticals (NASDAQ:REGN)<\/strong>, which presented a competing treatment alternative that it plans to launch in 2021. Roche Holding&#8217;s Genentech unit also presented an alternative treatment for a breast form of cancers where Merck&#8217;s Keytruda is also widely used.<\/p>\n<p>However, Merck executives are still upbeat about Keytriuda, an immune-oncology treatment that unmasks tumors for response by the body&#8217;s immune system. Currently, the blockbuster treatment has <a href=\"https:\/\/www.barrons.com\/articles\/mercks-lung-cancer-drug-is-a-blockbuster-other-companies-are-starting-to-challenge-its-dominance-51600805274\" target=\"_blank\" rel=\"noopener noreferrer\">approval for 30 cancer types<\/a> in the US and accounts for around 25% of its revenues.<\/p>\n<p>Roger Perlmutter, the company&#8217;s research chief, stated in a call that Merck currently has over 1,300 clinical trials that are on-going with the drug. Most of the studies were recently featured during the European Society form Medical Oncology virtual conference, which includes enhanced survival benefits against ovarian and esophagus cancer. Among the featured studies was the long-term survival follow-up in patients with lung cancer treated with Keytruda. Interestingly the blockbuster almost doubled the survival rate of 5 years to 32% relative to 16% in patients that received only chemotherapy treatment. Usually, cancers can develop resistance to chemotherapy, which is the case with Keytruda, but it staled lung cancers for around 29 months, which is 5 times longer compared to chemotherapy.<\/p>\n<p><strong>Regeneron\u2019s Libtayo to compete with Keytruda for lung cancer treatment <\/strong><\/p>\n<p>A competitor for Keytruda will be Regeneron&#8217;s Libtayo, which the company presented during the 2020 ESMO. The immune-oncology drug showed a reduction in death among lung cancer patients by almost 43% compared to chemotherapy over 11 month treatment period. According to Canaccord Genuity&#8217;s John Newman, the study could gain significant <a href=\"https:\/\/www.fiercepharma.com\/pharma\/regeneron-sanofi-won-t-dethrone-merck-lung-cancer-despite-strong-libtayo-data-analysts\" target=\"_blank\" rel=\"noopener noreferrer\">share for Regeneron and Sanofi<\/a>, its partner, once Libtayo gets approval for lung cancer treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Over the years, Merck &amp; Co\u2019s (NYSE:MRK) blockbuster cancer treatment, Keytruda, has been the standard first-line treatment alternative for most burdensome lung cancers, but this [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":15692,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[14692,14691,4507,1123,14694,14693],"stock_ticker":[14659],"class_list":["post-43642","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-merck-cos","tag-merck-cos-nysemrk","tag-nasdaqregn","tag-nysemrk","tag-regeneron-pharmaceuticals","tag-regeneron-pharmaceuticals-nasdaqregn","stock_ticker-mrk","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck &amp; Co\u2019s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck &amp; Co\u2019s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Over the years, Merck &amp; Co\u2019s (NYSE:MRK) blockbuster cancer treatment, Keytruda, has been the standard first-line treatment alternative for most burdensome lung cancers, but this [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-05T12:14:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"750\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Merck &#038; Co\u2019s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron\",\"datePublished\":\"2020-10-05T12:14:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642\"},\"wordCount\":345,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co.jpg\",\"keywords\":[\"Merck &amp; Co\u2019s\",\"Merck &amp; Co\u2019s (NYSE:MRK)\",\"NASDAQ:REGN\",\"NYSE:MRK\",\"Regeneron Pharmaceuticals\",\"Regeneron Pharmaceuticals (NASDAQ:REGN)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642\",\"name\":\"Merck & Co\u2019s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co.jpg\",\"datePublished\":\"2020-10-05T12:14:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co.jpg\",\"width\":1024,\"height\":750},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck &#038; Co\u2019s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck & Co\u2019s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642","og_locale":"en_US","og_type":"article","og_title":"Merck & Co\u2019s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron - Wall Street PR","og_description":"Over the years, Merck &amp; Co\u2019s (NYSE:MRK) blockbuster cancer treatment, Keytruda, has been the standard first-line treatment alternative for most burdensome lung cancers, but this [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2020-10-05T12:14:37+00:00","og_image":[{"width":1024,"height":750,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Merck &#038; Co\u2019s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron","datePublished":"2020-10-05T12:14:37+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642"},"wordCount":345,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co.jpg","keywords":["Merck &amp; Co\u2019s","Merck &amp; Co\u2019s (NYSE:MRK)","NASDAQ:REGN","NYSE:MRK","Regeneron Pharmaceuticals","Regeneron Pharmaceuticals (NASDAQ:REGN)"],"articleSection":["Health"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642","url":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642","name":"Merck & Co\u2019s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co.jpg","datePublished":"2020-10-05T12:14:37+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/Merck-Co.jpg","width":1024,"height":750},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/merck-cos-nysemrk-lung-cancer-treatment-dominance-with-keytruda-challenged-by-the-likes-of-regeneron-43642#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Merck &#038; Co\u2019s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/43642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=43642"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/43642\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/15692"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=43642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=43642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=43642"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=43642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}